§7–331.    IN EFFECT

    (a)    In this section, “Fund” means the Opioid Restitution Fund.

    (b)    There is an Opioid Restitution Fund.

    (c)    The purpose of the Fund is to retain the amount of settlement revenues deposited to the Fund in accordance with subsection (e)(1) of this section.

    (d)    (1)    The Fund is a special, nonlapsing fund that is not subject to § 7–302 of this subtitle.

        (2)    The State Treasurer shall hold the Fund separately, and the Comptroller shall account for the Fund.

    (e)    The Fund consists of:

        (1)    all revenues received by the State from any source resulting, directly or indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid research associations, or any other person in the opioid industry relating to any claims made or prosecuted by the State to recover damages for violations of State law; and

        (2)    the interest earnings of the Fund.

    (f)    The Fund may be used only to provide funds for the purposes specified in settlement agreements and judgments relating to claims by the State against opioid manufacturers, opioid research associations, or any other person in the opioid industry for violations of State law, including:

        (1)    programs, services, supports, and resources for evidence–based substance use disorder prevention, treatment, recovery, or harm reduction;

        (2)    supporting community–based nonprofit recovery organizations that provide nonclinical substance use recovery support services in the State;

        (3)    addressing racial disparities in access to prevention, harm reduction, treatment, and recovery support services;

        (4)    addressing socioeconomic disparities in access to prevention, harm reduction, treatment, and recovery support services;

        (5)    evidence–informed substance use disorder prevention, treatment recovery, or harm reduction pilot programs or demonstration studies that are not evidence–based if the Opioid Restitution Fund Advisory Council, established under § 7.5–902 of the Health – General Article:

            (i)    determines that emerging evidence supports the distribution of money for the pilot program or that there is a reasonable basis for funding the demonstration study with the expectation of creating an evidence–based program; and

            (ii)    approves the use of money for the pilot program or demonstration study;

        (6)    evaluations of the effectiveness and outcomes reporting for substance use disorder abatement infrastructure, programs, services, supports, and resources for which money from the Fund was used, including evaluations of the impact on access to harm reduction services or treatment for substance use disorders and the reduction in drug–related mortality;

        (7)    operating expenses and personnel costs for investigations, enforcement actions, and other activities conducted by the Opioids Enforcement Unit within the Office of the Attorney General that are related to the recovery of funds from opioid–related judgments or settlements; and

        (8)    the Buprenorphine Training Grant Program established under § 13–5802 of the Health – General Article.

    (g)    (1)    The State Treasurer shall invest the money of the Fund in the same manner as other State money may be invested.

        (2)    Any interest earnings of the Fund shall be credited to the Fund.

    (h)    (1)    Expenditures from the Fund may be made only in accordance with the State budget.

        (2)    For settlement funds received in accordance with the final distributor agreement of July 21, 2021, with McKesson Corporation, Amerisource Bergen Corporation, and Cardinal Health Incorporated, as amended, the Janssen settlement agreement of July 21, 2021, as amended, or any other opioid–related court or administrative judgment or settlement agreement involving the State and one or more of its political subdivisions:

            (i)    appropriations from the Fund in the State budget shall be made in accordance with the allocation and distribution of funds to the State and its political subdivisions:

                1.    as agreed on in the State–subdivision agreement of January 21, 2022, as amended; or

                2.    required under any other opioid–related court or administrative judgment or settlement agreement, or any similar agreement reached under an opioid–related court or administrative judgment or settlement agreement, involving the State and one or more of its political subdivisions; and

            (ii)    the Secretary of Health shall establish and administer a grant program for the distribution of funds to political subdivisions of the State in accordance with:

                1.    the State–subdivision agreement of January 21, 2022, as amended; or

                2.    the requirements of any other opioid–related court or administrative judgment or settlement agreement, or any similar agreement reached under an opioid–related court or administrative judgment or settlement agreement, involving the State and one or more of its political subdivisions.

        (3)    The Attorney General shall identify and designate the controlling version of any agreement or amendment described under paragraph (2) of this subsection.

    (i)    (1)    (i)    This paragraph does not apply in fiscal years 2025 and 2026.

            (ii)    Money expended from the Fund for the programs and services described under subsection (f) of this section is supplemental to and is not intended to take the place of funding that otherwise would be appropriated for the programs and services.

        (2)    Except as specified in subsection (f) of this section, money expended from the Fund may not be used for administrative expenses.

    (j)    The Governor shall:

        (1)    develop key goals, key objectives, and key performance indicators relating to substance use treatment and prevention efforts;

        (2)    subject to subsection (h)(2) of this section, at least twice annually, consult with the Opioid Restitution Fund Advisory Council to identify recommended appropriations from the Fund; and

        (3)    report on or before November 1 each year, in accordance with § 2–1257 of the State Government Article, to the General Assembly on:

            (i)    an accounting of total funds expended from the Fund in the immediately preceding fiscal year, by:

                1.    use;

                2.    if applicable, jurisdiction; and

                3.    budget program and subdivision;

            (ii)    the performance indicators and progress toward achieving the goals and objectives developed under item (1) of this subsection; and

            (iii)    the recommended appropriations from the Fund identified in accordance with item (2) of this subsection.

    (k)    Beginning on or before October 1, 2025, and each October 1 thereafter, the Office of the Attorney General shall report to the Governor and, in accordance with § 2–1257 of the State Government Article, the General Assembly on the status of activity of the Opioids Enforcement Unit, including:

        (1)    the number of investigations taking place;

        (2)    the number of lawsuits filed; and

        (3)    the disposition of lawsuits filed.

§7–331.    // EFFECTIVE JUNE 30, 2029 PER CHAPTERS 700 AND 701 OF 2025 //

    // EFFECTIVE UNTIL SEPTEMBER 30, 2030 PER CHAPTER 759 OF 2025 //

    (a)    In this section, “Fund” means the Opioid Restitution Fund.
    

    (b)    There is an Opioid Restitution Fund.

    (c)    The purpose of the Fund is to retain the amount of settlement revenues deposited to the Fund in accordance with subsection (e)(1) of this section.

    (d)    (1)    The Fund is a special, nonlapsing fund that is not subject to § 7–302 of this subtitle.

        (2)    The State Treasurer shall hold the Fund separately, and the Comptroller shall account for the Fund.

    (e)    The Fund consists of:

        (1)    all revenues received by the State from any source resulting, directly or indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid research associations, or any other person in the opioid industry relating to any claims made or prosecuted by the State to recover damages for violations of State law; and

        (2)    the interest earnings of the Fund.

    (f)    The Fund may be used only to provide funds for the purposes specified in settlement agreements and judgments relating to claims by the State against opioid manufacturers, opioid research associations, or any other person in the opioid industry for violations of State law, including:

        (1)    programs, services, supports, and resources for evidence–based substance use disorder prevention, treatment, recovery, or harm reduction;

        (2)    supporting community–based nonprofit recovery organizations that provide nonclinical substance use recovery support services in the State;

        (3)    addressing racial disparities in access to prevention, harm reduction, treatment, and recovery support services;

        (4)    addressing socioeconomic disparities in access to prevention, harm reduction, treatment, and recovery support services;
    

        (5)    evidence–informed substance use disorder prevention, treatment recovery, or harm reduction pilot programs or demonstration studies that are not evidence–based if the Opioid Restitution Fund Advisory Council, established under § 7.5–902 of the Health – General Article:

            (i)    determines that emerging evidence supports the distribution of money for the pilot program or that there is a reasonable basis for funding the demonstration study with the expectation of creating an evidence–based program; and

            (ii)    approves the use of money for the pilot program or demonstration study;

        (6)    evaluations of the effectiveness and outcomes reporting for substance use disorder abatement infrastructure, programs, services, supports, and resources for which money from the Fund was used, including evaluations of the impact on access to harm reduction services or treatment for substance use disorders and the reduction in drug–related mortality; and

        (7)    the Buprenorphine Training Grant Program established under § 13–5802 of the Health – General Article.

    (g)    (1)    The State Treasurer shall invest the money of the Fund in the same manner as other State money may be invested.

        (2)    Any interest earnings of the Fund shall be credited to the Fund.

    (h)    (1)    Expenditures from the Fund may be made only in accordance with the State budget.

        (2)    For settlement funds received in accordance with the final distributor agreement of July 21, 2021, with McKesson Corporation, Amerisource Bergen Corporation, and Cardinal Health Incorporated, as amended, the Janssen settlement agreement of July 21, 2021, as amended, or any other opioid–related court or administrative judgment or settlement agreement involving the State and one or more of its political subdivisions:

            (i)    appropriations from the Fund in the State budget shall be made in accordance with the allocation and distribution of funds to the State and its political subdivisions:

                1.    as agreed on in the State–subdivision agreement of January 21, 2022, as amended; or

                2.    required under any other opioid–related court or administrative judgment or settlement agreement, or any similar agreement reached under an opioid–related court or administrative judgment or settlement agreement, involving the State and one or more of its political subdivisions; and

            (ii)    the Secretary of Health shall establish and administer a grant program for the distribution of funds to political subdivisions of the State in accordance with:

                1.    the State–subdivision agreement of January 21, 2022, as amended; or

                2.    the requirements of any other opioid–related court or administrative judgment or settlement agreement, or any similar agreement reached under an opioid–related court or administrative judgment or settlement agreement, involving the State and one or more of its political subdivisions.

        (3)    The Attorney General shall identify and designate the controlling version of any agreement or amendment described under paragraph (2) of this subsection.

    (i)    (1)    (i)    This paragraph does not apply in fiscal years 2025 and 2026.

            (ii)    Money expended from the Fund for the programs and services described under subsection (f) of this section is supplemental to and is not intended to take the place of funding that otherwise would be appropriated for the programs and services.

        (2)    Except as specified in subsection (f) of this section, money expended from the Fund may not be used for administrative expenses.

    (j)    The Governor shall:

        (1)    develop key goals, key objectives, and key performance indicators relating to substance use treatment and prevention efforts;

        (2)    subject to subsection (h)(2) of this section, at least twice annually, consult with the Opioid Restitution Fund Advisory Council to identify recommended appropriations from the Fund; and

        (3)    report on or before November 1 each year, in accordance with § 2–1257 of the State Government Article, to the General Assembly on:

            (i)    an accounting of total funds expended from the Fund in the immediately preceding fiscal year, by:

                1.    use;

                2.    if applicable, jurisdiction; and

                3.    budget program and subdivision;

            (ii)    the performance indicators and progress toward achieving the goals and objectives developed under item (1) of this subsection; and

            (iii)    the recommended appropriations from the Fund identified in accordance with item (2) of this subsection.

§7–331.    // EFFECTIVE SEPTEMBER 30, 2030 PER CHAPTER 759 OF 2025 //

    (a)    In this section, “Fund” means the Opioid Restitution Fund.

    (b)    There is an Opioid Restitution Fund.

    (c)    The purpose of the Fund is to retain the amount of settlement revenues deposited to the Fund in accordance with subsection (e)(1) of this section.

    (d)    (1)    The Fund is a special, nonlapsing fund that is not subject to § 7–302 of this subtitle.

        (2)    The State Treasurer shall hold the Fund separately, and the Comptroller shall account for the Fund.

    (e)    The Fund consists of:

        (1)    all revenues received by the State from any source resulting, directly or indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid research associations, or any other person in the opioid industry relating to any claims made or prosecuted by the State to recover damages for violations of State law; and

        (2)    the interest earnings of the Fund.

    (f)    The Fund may be used only to provide funds for the purposes specified in settlement agreements and judgments relating to claims by the State against opioid manufacturers, opioid research associations, or any other person in the opioid industry for violations of State law, including:

        (1)    programs, services, supports, and resources for evidence–based substance use disorder prevention, treatment, recovery, or harm reduction;

        (2)    supporting community–based nonprofit recovery organizations that provide nonclinical substance use recovery support services in the State;

        (3)    addressing racial disparities in access to prevention, harm reduction, treatment, and recovery support services;

        (4)    addressing socioeconomic disparities in access to prevention, harm reduction, treatment, and recovery support services;

        (5)    evidence–informed substance use disorder prevention, treatment recovery, or harm reduction pilot programs or demonstration studies that are not evidence–based if the Opioid Restitution Fund Advisory Council, established under § 7.5–902 of the Health – General Article:

            (i)    determines that emerging evidence supports the distribution of money for the pilot program or that there is a reasonable basis for funding the demonstration study with the expectation of creating an evidence–based program; and

            (ii)    approves the use of money for the pilot program or demonstration study; and

        (6)    evaluations of the effectiveness and outcomes reporting for substance use disorder abatement infrastructure, programs, services, supports, and resources for which money from the Fund was used, including evaluations of the impact on access to harm reduction services or treatment for substance use disorders and the reduction in drug–related mortality.

    (g)    (1)    The State Treasurer shall invest the money of the Fund in the same manner as other State money may be invested.

        (2)    Any interest earnings of the Fund shall be credited to the Fund.

    (h)    (1)    Expenditures from the Fund may be made only in accordance with the State budget.

        (2)    For settlement funds received in accordance with the final distributor agreement of July 21, 2021, with McKesson Corporation, Amerisource Bergen Corporation, and Cardinal Health Incorporated, as amended, the Janssen settlement agreement of July 21, 2021, as amended, or any other opioid–related court or administrative judgment or settlement agreement involving the State and one or more of its political subdivisions:

            (i)    appropriations from the Fund in the State budget shall be made in accordance with the allocation and distribution of funds to the State and its political subdivisions:

                1.    as agreed on in the State–subdivision agreement of January 21, 2022, as amended; or

                2.    required under any other opioid–related court or administrative judgment or settlement agreement, or any similar agreement reached under an opioid–related court or administrative judgment or settlement agreement, involving the State and one or more of its political subdivisions; and

            (ii)    the Secretary of Health shall establish and administer a grant program for the distribution of funds to political subdivisions of the State in accordance with:

                1.    the State–subdivision agreement of January 21, 2022, as amended; or

                2.    the requirements of any other opioid–related court or administrative judgment or settlement agreement, or any similar agreement reached under an opioid–related court or administrative judgment or settlement agreement, involving the State and one or more of its political subdivisions.

        (3)    The Attorney General shall identify and designate the controlling version of any agreement or amendment described under paragraph (2) of this subsection.

    (i)    (1)    (i)    This paragraph does not apply in fiscal years 2025 and 2026.

            (ii)    Money expended from the Fund for the programs and services described under subsection (f) of this section is supplemental to and is not intended to take the place of funding that otherwise would be appropriated for the programs and services.

        (2)    Except as specified in subsection (f) of this section, money expended from the Fund may not be used for administrative expenses.

    (j)    The Governor shall:

        (1)    develop key goals, key objectives, and key performance indicators relating to substance use treatment and prevention efforts;

        (2)    subject to subsection (h)(2) of this section, at least twice annually, consult with the Opioid Restitution Fund Advisory Council to identify recommended appropriations from the Fund; and

        (3)    report on or before November 1 each year, in accordance with § 2–1257 of the State Government Article, to the General Assembly on:

            (i)    an accounting of total funds expended from the Fund in the immediately preceding fiscal year, by:

                1.    use;

                2.    if applicable, jurisdiction; and

                3.    budget program and subdivision;

            (ii)    the performance indicators and progress toward achieving the goals and objectives developed under item (1) of this subsection; and

            (iii)    the recommended appropriations from the Fund identified in accordance with item (2) of this subsection.